Curis Inc

Biotechnology company Curis reported a narrowed Q2 2025 net loss of $0.68 per share, beating analyst expectations. The company continues advancing its cancer therapy emavusertib while facing near-term funding challenges, with cash reserves expected to last only into Q1 2026.

VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from exi...

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price actio...

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: RL) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintaine...